1. A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation. Issue 12 (14th August 2020) Authors: Kishi, Haruka; Jojima, Teruo; Kogai, Takahiko; Iijima, Toshie; Ohira, Eriko; Tanuma, Dai; Konno, Sachiyo; Kato, Kanako; Kezuka, Atsumi; Akimoto, Kazumi; Sakumoto, Junko; Hishinuma, Akira; Tomaru, Takuya; Makita, Noriko; Usui, Isao; Aso, Yoshimasa Journal: Clinical case reports Issue: Volume 8:Issue 12(2020) Page Start: 2619 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Acute effect of add‐on therapy with tofogliflozin, a sodium glucose co‐transporter 2 inhibitor, on 24‐hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase‐4 inhibitors. Issue 11 (19th August 2021) Authors: Iijima, Toshie; Hosonuma, Soichiro; Kurai, Hidetaka; Kajitani, Hayato; Sakurai, Shintaro; Tomaru, Takuya; Jojima, Teruo; Usui, Isao; Aso, Yoshimasa Journal: International journal of clinical practice Issue: Volume 75:Issue 11(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication. Issue 10 (30th August 2020) Authors: Shinohara, Yasutake; Iijima, Toshie; Sakurai, Shintaro; Jojima, Teruo; Ohira, Eriko; Hayashi, Shujiro; Usui, Isao; Igawa, Ken; Aso, Yoshimasa Journal: Clinical case reports Issue: Volume 8:Issue 10(2020) Page Start: 2007 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells. (November 2017) Authors: Iijima, Toshie; Kato, Kanako; Jojima, Teruo; Tomotsune, Takanori; Fukushima, Maiko; Suzuki, Kunihiro; Aso, Yoshimasa Journal: Diabetes research and clinical practice Issue: Volume 133(2017) Page Start: 10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co‐formulation therapy twice‐daily with free combination of GLP‐1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial. Issue 4 (9th November 2020) Authors: Aso, Yoshimasa; Takada, Yoshihisa; Tomotsune, Ken; Chiba, Yasuko; Matsumura, Mihoko; Jojima, Teruo; Sato, Minoru; Fujita, Nobuya; Kuroda, Hisamoto; Murano, Shunichi; Usui, Isao Journal: International journal of clinical practice Issue: Volume 75:Issue 4(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effects of treatment with methimazole on circulating CD4+ and CD8+ T cells positive for programed cell death protein‐1 and on subsets of CD4+ T cells in untreated hyperthyroid patients with Graves' disease. (17th June 2022) Authors: Hirao, Nanako; Iijima, Toshie; Tanuma, Dai; Ohira, Eriko; Kurai, Hidetaka; Shinzawa, Toshimitsu; Kase, Masato; Sakurai, Shintaro; Tomaru, Takuya; Jojima, Teruo; Usui, Isao; Aso, Yoshimasa Journal: Clinical endocrinology Issue: Volume 97:Number 6(2022) Page Start: 841 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Issue 1 (December 2016) Authors: Jojima, Teruo; Tomotsune, Takanori; Iijima, Toshie; Akimoto, Kazumi; Suzuki, Kunihiro; Aso, Yoshimasa Journal: Diabetology & metabolic syndrome Issue: Volume 8:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. (15th May 2021) Authors: Jojima, Teruo; Sakurai, Shintaro; Wakamatsu, Sho; Iijima, Toshie; Saito, Masahiro; Tomaru, Takuya; Kogai, Takahiko; Usui, Isao; Aso, Yoshimasa Journal: International journal of cardiology Issue: Volume 331(2021) Page Start: 243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease. Issue 2 (2nd October 2018) Authors: Shimizu, Masanori; Suzuki, Kunihiro; Kato, Kanako; Jojima, Teruo; Iijima, Toshie; Murohisa, Toshimitsu; Iijima, Makoto; Takekawa, Hidehiro; Usui, Isao; Hiraishi, Hideyuki; Aso, Yoshimasa Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 2(2019) Page Start: 285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Expectations for synergistically favorable effects of the combination therapy with DPP-4 inhibitor and SGLT2 inhibitor on cholesterol synthesis and absorption. (15th June 2021) Authors: Jojima, Teruo Journal: International journal of cardiology Issue: Volume 333(2021) Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗